Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | AGXT | P21549 | 2/20 | 0.50 |
| ▸ | DAO | P14920 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 4/20 | 0.44 |
| ▸ | HTR2C | P28335 | 4/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | XBP1 | P17861 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | F2RL1 | P55085 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30636758 | 1.00 | IDO1 (0.50) | IDO1AGXTDAOKDM4ESMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL6193006 | 0.98 | IDO1 (0.48) | IDO1AGXTDAOKDM4ESMN1; SMN2 | |
| SCHEMBL13349755 | 0.87 | TYR (0.50) | IDO1AGXTDAOKDM4ESMN1; SMN2 | |
| SCHEMBL7700904 | 0.85 | IDO1 (0.58) | IDO1AGXTDAOKDM4ESMN1; SMN2 | |
| SCHEMBL19275390 | 0.85 | TYR (0.50) | IDO1AGXTDAOKDM4ESMN1; SMN2 | |
| SCHEMBL21505683 | 0.84 | TYR (0.53) | IDO1AGXTDAOHTR2AMAPT | |
| SCHEMBL4481161 | 0.82 | RIPK1 (0.44) | IDO1AGXTSMN1; SMN2HTR2AHTR2C | |
| SCHEMBL469184 | 0.81 | IDO1 (0.54) | IDO1AGXTDAOKDM4ESMN1; SMN2 | |
| SCHEMBL9921236 | 0.80 | TAAR1 (0.41) | HTR2A | |
| SCHEMBL12656571 | 0.80 | MAPT (0.41) | IDO1AGXTSMN1; SMN2RIPK1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105601469-A | Synthesizing method of 1-(1-chloromethyl vinyl)-2, 4-difluorobenzene | NINGBO XINKAI BIOTECHNOLOGY CO LTD | 2016-05-25 | — | — | CN | claimed |
| CN-120029007-A | Colored photosensitive resin composition, partition wall, organic electroluminescent element, image display device, and illumination | 三菱化学株式会社 | 2025-05-23 | — | — | CN | disclosed |
| CN-111566561-B | Colored photosensitive resin composition, partition wall, organic electroluminescent element, image display device, and illumination | 三菱化学株式会社 | 2025-02-14 | — | — | CN | disclosed |
| US-20240068009-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES | PROMEGA CORPORATION | 2024-02-29 | — | — | US | disclosed |
| WO-2023235548-A1 | SQUARAMIDE DERIVATIVES AS CB1 ALLOSTERIC MODULATORS | RESEARCH TRIANGLE INSTITUTE (US) | 2023-12-07 | — | — | WO | disclosed |
| US-11781168-B2 | Process for preparing substituted imidazo[1,2-α]pyrazines | PROMEGA CORPORATION (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-10-05 | — | — | US | disclosed |
| EP-4230620-A1 | SUBSTITUTED N-AMINO-N-BENZOIC ACID URACILS, THEIR SALTS AND USE OF SAID COMPOUNDS AS HERBICIDAL AGENTS | Bayer Aktiengesellschaft (DE) | 2023-08-23 | — | — | EP | disclosed |
| US-20230257382-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-11634425-B2 | Pharmaceutical compounds | PFIZER INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-7531556-B2 | Compositions useful as inhibitors of rock and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-05-12 | — | — | US | disclosed |
| US-20090099096-A1 | AZA-peptide protease inhibitors | GILEAD SCIENCES, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090082367-A1 | TRIAZOLE DERIVATIVE OR A SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-03-26 | — | — | US | disclosed |
| US-20090082367-A1 | TRIAZOLE DERIVATIVE OR A SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-03-26 | — | — | US | disclosed |
| US-20090036506-A1 | 5-Iodotetrazoles | LANXESS DEUTSCHLAND GMBH (DE) | 2009-02-05 | — | — | US | disclosed |
| US-20090036506-A1 | 5-Iodotetrazoles | LANXESS DEUTSCHLAND GMBH (DE) | 2009-02-05 | — | — | US | disclosed |
| EP-1995243-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2008-11-26 | — | — | EP | disclosed |
| US-20080269322-A1 | Substituted Aminophenylsulfonamide Compounds as Hiv Protease Inhibitor | JANSSEN SCIENCES IRELAND UC (IE) | 2008-10-30 | — | — | US | disclosed |
| US-20080146569-A1 | Nicotinamide Derivatives | PFIZER INC. | 2008-06-19 | — | — | US | disclosed |
| EP-1773125-B1 | 5-IODOTETRAZOLES | LANXESS DEUTSCHLAND GMBH (DE) | 2008-05-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11781168-B2 | Process for preparing substituted imidazo[1,2-α]pyrazines | CYP4Z1, CYP2E1, CYP2F1 | IDO1 624/4885AGXT 3267/4885DAO 2218/4885 |
| US-20090036506-A1 | 5-Iodotetrazoles | GPX4, CYP1A1, CYP2E1 | IDO1 71/4885AGXT 1731/4885DAO 2069/4885 |
| US-20080146569-A1 | Nicotinamide Derivatives | NNT, NAMPT, NADK | IDO1 627/4885AGXT 3543/4885DAO 2454/4885 |
| US-20080269322-A1 | Substituted Aminophenylsulfonamide Compounds as Hiv Protease Inhibitor | DNPEP, ANPEP, NPEPPS | IDO1 757/4885AGXT 673/4885DAO 194/4885 |
| US-20240068009-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES | PGLS, AADAC, GLB1 | IDO1 857/4885AGXT 193/4885DAO 452/4885 |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | DPYD, PKD1, TYMP | IDO1 952/4885AGXT 2544/4885DAO 1329/4885 |
| US-11634425-B2 | Pharmaceutical compounds | GABRA6, CHRNA6, CNR1 | IDO1 2344/4885AGXT 3360/4885DAO 1576/4885 |
| US-20090099096-A1 | AZA-peptide protease inhibitors | DNPEP, ANPEP, PEPD | IDO1 1815/4885AGXT 1401/4885DAO 1461/4885 |
| US-20090082367-A1 | TRIAZOLE DERIVATIVE OR A SALT THEREOF | HSD11B1, HSD11B2, HSD17B1 | IDO1 1490/4885AGXT 652/4885DAO 1109/4885 |
| US-20230257382-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TRPC5, TRPC1, GOT1 | IDO1 184/4885AGXT 783/4885DAO 2159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.